Zinc Restriction Cut Testosterone by 73 Percent in Four Healthy Men, and 30 mg a Day Nearly Doubled It in Nine Deficient Older Men. In Men Who Already Get Enough, Three Trials Found Nothing, and Supplement Doses Over 100 mg Doubled the Risk of Advanced Prostate Cancer in 46,974 Men.
Zinc occupies a different position from every herb sold to men for testosterone. Nobody disputes that testosterone cannot be made without it. The enzymes in the Leydig cell that turn cholesterol into androgens are zinc dependent, the androgen receptor cannot bind DNA without two zinc atoms folded into its structure, and the human testis holds more zinc per gram than almost any tissue except the prostate. The question is not whether zinc matters but whether a supplement does anything for a man who is already getting enough, and the human trials answer that question more cleanly than they do for any other testosterone supplement. This article walks through the deprivation studies that show what happens when zinc is removed, the repletion studies that show what happens when it is restored, the one double-blind placebo-controlled trial that exists, the three ZMA studies in athletes that found nothing, the 2023 systematic review that pulled it together, and the safety data that matter most for men over 40: a 40 mg upper limit, copper depletion above 50 mg, and a large cohort in which men taking more than 100 mg a day developed advanced prostate cancer at more than twice the rate of non-users.
Key Takeaways: What the Zinc and Testosterone Evidence Actually Shows
Zinc restriction lowers testosterone in healthy men, and zinc repletion raises it in men who were deficient, but zinc supplementation does not raise testosterone in men whose diet already supplies enough. In the 1996 Prasad study published in Nutrition, four healthy young men fed a zinc-restricted diet for 20 weeks saw serum testosterone fall from 39.9 to 10.6 nmol/L, roughly 1,150 to 306 ng/dL, a 73 percent drop; nine marginally zinc-deficient men with a mean age of 64 given 30 mg of zinc gluconate a day for three to six months saw testosterone rise from 8.3 to 16.0 nmol/L, roughly 239 to 461 ng/dL. The only double-blind placebo-controlled zinc trial with testosterone as an endpoint, Mahajan 1982 in the Annals of Internal Medicine, gave 20 men on hemodialysis 50 mg of elemental zinc as zinc acetate or placebo for six months and found testosterone rose from 2.8 to 5.2 ng/mL, or 280 to 520 ng/dL, with sperm count doubling from 30 to 63 million per mL and luteinizing hormone falling by half, none of which happened on placebo. Netter 1981 gave zinc to 37 men with unexplained infertility and found testosterone rose only in the 22 who started below 4.8 ng/mL; nine of their wives became pregnant. In men who already consume 12 to 23 mg of zinc a day, ZMA at 30 mg of zinc did not change total or free testosterone in Koehler 2009 (14 men, 56 days) or Wilborn 2004 (42 resistance-trained men, 8 weeks), and the one positive ZMA trial, Brilla 2000 in 27 football players, was funded by the company that made the product and has never been replicated. A 2023 systematic review of 8 human and 30 animal studies concluded that zinc deficiency lowers testosterone and moderate supplementation restores it, with the size of the effect depending on starting zinc and testosterone levels, dose, form and duration. The recommended daily allowance for men is 11 mg, the tolerable upper limit is 40 mg, doses of 50 mg or more taken for months cause copper deficiency, and in the Health Professionals Follow-up Study men taking more than 100 mg of supplemental zinc a day had a relative risk of 2.29 for advanced prostate cancer, rising to 2.37 after ten or more years of use.
Ten Studies, 284 Men, One Double-Blind Trial, and a Pattern That Depends on Where Men Started
Men enrolled in each human zinc study that measured serum testosterone, 1981 to 2010. Red marks deprivation studies in which testosterone fell when dietary zinc was removed: Prasad 1996 fed four healthy men about 1 mg a day for 20 weeks and Hunt 1992 fed eleven men 1.4 mg a day for 35 days. Green marks studies where testosterone rose against a placebo group: Mahajan 1982, the only double-blind trial, and Brilla 2000, the manufacturer-funded ZMA study whose result has not replicated. Amber marks repletion studies with a rise against baseline only, because there was no placebo arm: Netter 1981, Prasad's nine older men, the Kilic exercise studies and Jalali 2010. Grey marks the two controlled ZMA studies in men with adequate zinc intake that found no change in total or free testosterone: Wilborn 2004 and Koehler 2009. Every study that found a rise enrolled men who were deficient or likely to be; every study in men known to be replete found nothing.
Why would zinc affect testosterone at all?
Zinc is required at three separate points in the testosterone system: the enzymes that make the hormone, the receptor that reads it, and the pituitary signal that tells the testis to produce it. Zinc is a cofactor for more than 300 enzymes and a structural element in more than 2,000 proteins, and the steroidogenic pathway in the Leydig cell, from cholesterol side-chain cleavage through 3-beta-hydroxysteroid dehydrogenase and 17-beta-hydroxysteroid dehydrogenase, depends on zinc-containing enzymes at several steps. Rats made zinc deficient show shrunken Leydig cells that respond poorly to a gonadotropin challenge, and the effect reverses when zinc is restored. The androgen receptor belongs to the nuclear receptor family whose DNA-binding domain is built from two zinc fingers, each folded around a single zinc ion; without zinc the receptor cannot grip the DNA sequences that testosterone is supposed to switch on. At the pituitary, zinc deficiency in animals blunts luteinizing hormone secretion, and in the human dialysis trials the pattern of falling LH alongside rising testosterone after repletion suggests the testis was the site of the problem and the pituitary had been shouting to compensate. Two further mechanisms appear in the marketing more than the literature. Zinc inhibits aromatase, the enzyme that converts testosterone to estradiol, in cell culture at concentrations that have not been shown to be reached by supplementation. And an in vitro study from 1984 found that low zinc concentrations stimulated 5-alpha-reductase while high concentrations inhibited it, which is sometimes cited as evidence that zinc raises or lowers dihydrotestosterone depending on who is selling what. The human data on DHT are thin: in Netter 1981, DHT rose in both the low and normal testosterone groups. The point that matters is simpler than any of this. Zinc is a requirement, not a stimulant, and a requirement only shows its effect when it is missing.
Ten Studies, 284 Men, One Double-Blind Trial, and a Pattern That Depends on Where Men Started
Men enrolled in each human zinc study that measured serum testosterone, 1981 to 2010. Red marks deprivation studies in which testosterone fell when dietary zinc was removed: Prasad 1996 fed four healthy men about 1 mg a day for 20 weeks and Hunt 1992 fed eleven men 1.4 mg a day for 35 days. Green marks studies where testosterone rose against a placebo group: Mahajan 1982, the only double-blind trial, and Brilla 2000, the manufacturer-funded ZMA study whose result has not replicated. Amber marks repletion studies with a rise against baseline only, because there was no placebo arm: Netter 1981, Prasad's nine older men, the Kilic exercise studies and Jalali 2010. Grey marks the two controlled ZMA studies in men with adequate zinc intake that found no change in total or free testosterone: Wilborn 2004 and Koehler 2009. Every study that found a rise enrolled men who were deficient or likely to be; every study in men known to be replete found nothing.
What happens to testosterone when healthy men are deprived of zinc?
Deliberate zinc restriction in healthy men lowers serum testosterone, and the effect in the longest study was a 73 percent fall over 20 weeks. Ananda Prasad, the physician who first described human zinc deficiency in Iranian and Egyptian adolescents in the early 1960s, published the key experiment in Nutrition in 1996. Four healthy young men were fed a diet supplying only about 1 mg of zinc a day, against a recommended intake of 11 mg, and were followed for 20 weeks. Serum testosterone fell from 39.9 to 10.6 nmol/L, which converts to roughly 1,150 to 306 ng/dL, taking men from the upper end of the normal range to the threshold most guidelines use to define biochemical hypogonadism. The same paper reported that among 40 healthy men aged 20 to 80, cellular zinc in lymphocytes and granulocytes correlated with serum testosterone, and that older men had lower values of both. A second deprivation study, Hunt and colleagues at the USDA Human Nutrition Research Center in Grand Forks, published in the American Journal of Clinical Nutrition in 1992, fed 11 men 1.4 mg of zinc a day for 35 days and found semen volume, seminal zinc loss and serum testosterone all declined, with changes in sperm morphology. Both studies are small, neither had a parallel control group, and both used restriction far more severe than anything an ordinary Western diet produces. Their value is not as a model of typical deficiency but as proof of dependence: remove zinc and the testosterone system fails, which no herb in the supplement category can claim. The scale of the fall in the Prasad study, three quarters of the starting value in five months, is larger than the effect of almost any drug short of a GnRH antagonist, and it is the reason zinc keeps appearing on testosterone supplement labels three decades later.
Take Zinc Away and Testosterone Falls by Three Quarters. Give It Back and It Nearly Doubles.
Mean serum testosterone in ng/dL before and after each intervention in Prasad and colleagues, Nutrition 1996, converted from nmol/L at 28.84. In the restriction experiment, four healthy young men were fed a diet supplying about 1 mg of zinc a day, against a recommended 11 mg, for 20 weeks; serum testosterone fell from 39.9 to 10.6 nmol/L, roughly 1,151 to 306 ng/dL, a 73 percent decline that took the group from the upper end of the normal range to the hypogonadal threshold. In the repletion experiment, nine men with a mean age of 64 who were marginally zinc deficient by cellular measurement took 459 micromoles of zinc a day as zinc gluconate, which is 30 mg of elemental zinc, for three to six months; serum testosterone rose from 8.3 to 16.0 nmol/L, roughly 239 to 461 ng/dL. The dashed line marks 300 ng/dL, the cut-off most guidelines use for biochemical hypogonadism. Neither experiment had a parallel control group, and the restriction was far more severe than any ordinary diet produces. The same paper reported that cellular zinc correlated with serum testosterone across 40 healthy men aged 20 to 80.
- Before
- After
Does zinc supplementation raise testosterone in men who are deficient?
In every human study of men with documented or probable zinc deficiency, zinc supplementation raised serum testosterone, and in the largest the rise was 46 percent. The clearest repletion data come from the second half of the Prasad 1996 paper: nine men with a mean age of 64, plus or minus 9 years, who were marginally zinc deficient by cellular measurement, took 459 micromoles of zinc a day as zinc gluconate, which is 30 mg of elemental zinc, for three to six months. Serum testosterone rose from 8.3 to 16.0 nmol/L, roughly 239 to 461 ng/dL, taking the group mean from below the hypogonadal threshold to the middle of the normal range. There was no placebo arm. Netter, Hartoma and Nahoul published the earliest supplementation study in Archives of Andrology in 1981: 37 men with idiopathic infertility of more than five years' duration were given oral zinc, and the analysis split them by baseline testosterone. In the 22 men who started below 4.8 ng/mL, testosterone, dihydrotestosterone and sperm count all rose significantly, and nine wives became pregnant, six within three months. In the 15 men who started above 4.8 ng/mL, testosterone and sperm count did not change, though DHT rose. That split, a response in men who start low and nothing in men who start normal, is the single most consistent finding across the zinc literature and mirrors what the tongkat ali and vitamin D trials show. The largest repletion study is Jalali and colleagues in Renal Failure in 2010: 100 men on hemodialysis, a population in which zinc deficiency is close to universal because the metal is lost in dialysate and poorly absorbed, took 250 mg of zinc sulfate a day, about 57 mg of elemental zinc, for six weeks; 95 completed, and mean testosterone rose from 277 to 405 ng/dL while LH rose from 4.85 to 15.77 mIU/mL and FSH did not change. There was no placebo group. None of these three studies was blinded, and regression to the mean in a group selected for low values is a real concern in the Netter subgroup analysis, which is why the one double-blind trial matters so much.
Take Zinc Away and Testosterone Falls by Three Quarters. Give It Back and It Nearly Doubles.
Mean serum testosterone in ng/dL before and after each intervention in Prasad and colleagues, Nutrition 1996, converted from nmol/L at 28.84. In the restriction experiment, four healthy young men were fed a diet supplying about 1 mg of zinc a day, against a recommended 11 mg, for 20 weeks; serum testosterone fell from 39.9 to 10.6 nmol/L, roughly 1,151 to 306 ng/dL, a 73 percent decline that took the group from the upper end of the normal range to the hypogonadal threshold. In the repletion experiment, nine men with a mean age of 64 who were marginally zinc deficient by cellular measurement took 459 micromoles of zinc a day as zinc gluconate, which is 30 mg of elemental zinc, for three to six months; serum testosterone rose from 8.3 to 16.0 nmol/L, roughly 239 to 461 ng/dL. The dashed line marks 300 ng/dL, the cut-off most guidelines use for biochemical hypogonadism. Neither experiment had a parallel control group, and the restriction was far more severe than any ordinary diet produces. The same paper reported that cellular zinc correlated with serum testosterone across 40 healthy men aged 20 to 80.
- Before
- After
What did the only double-blind placebo-controlled trial show?
The only double-blind placebo-controlled trial of zinc with testosterone as a primary endpoint found that 50 mg of elemental zinc a day for six months raised testosterone from 280 to 520 ng/dL in men on hemodialysis, with no change on placebo. Mahajan and colleagues at Wayne State University published the trial in the Annals of Internal Medicine in 1982. Twenty stable men receiving hemodialysis three times a week were randomized to 50 mg of elemental zinc as zinc acetate or an identical placebo, ten in each group, taken orally for six months. In the zinc group, plasma zinc rose from 75 to 100 micrograms per decilitre, serum testosterone rose from 2.8 to 5.2 ng/mL, and sperm count rose from 30 to 63 million per mL, each significant at p under 0.001. Luteinizing hormone fell from 92 to 49 mIU/mL and follicle-stimulating hormone from 45 to 25, both significant. The placebo group showed none of these changes. The hormone pattern is the important part: a testosterone rise accompanied by a fall in the pituitary signals that drive it means the testis had become more responsive, not that the pituitary had been stimulated. That is what repletion of a missing cofactor should look like, and it is the opposite of what a drug like clomiphene or enclomiphene does. Two cautions apply. The trial is small, 20 men and 10 per arm. And uremic men are an extreme case, with plasma zinc that started at 75 micrograms per decilitre, near the bottom of the normal range, and a dialysis process that strips the metal continuously. A 1980 Lancet study by Brook and colleagues found that zinc did not improve sexual dysfunction in dialysis patients, though it did not report testosterone in the same way, and the Jalali authors 30 years later were careful to say that a hormone rise had not translated into a demonstrated sexual benefit. The trial establishes that zinc repletion raises testosterone in deficient men under blinded conditions. It says nothing about men whose zinc is normal.
Testosterone Up 86 Percent, Sperm Count Doubled, and the Pituitary Signals Fell by Half
Percent change from baseline to six months in the zinc group of Mahajan and colleagues, Annals of Internal Medicine 1982, the only double-blind placebo-controlled zinc trial with testosterone as an endpoint. Twenty stable men on hemodialysis three times a week were randomized to 50 mg of elemental zinc as zinc acetate or placebo, ten per arm. In the zinc group plasma zinc rose from 75 to 100 micrograms per decilitre, serum testosterone from 2.8 to 5.2 ng/mL, and sperm count from 30 to 63 million per mL, each at p under 0.001; luteinizing hormone fell from 92 to 49 mIU/mL at p under 0.005 and follicle-stimulating hormone from 45 to 25 at p under 0.05. The placebo group showed none of these changes. A testosterone rise accompanied by a fall in the gonadotropins that drive it is the signature of a testis that has become more responsive, which is what repletion of a missing cofactor should look like. The men were uremic and started with plasma zinc near the bottom of the normal range, so the result describes correction of deficiency and not enhancement in replete men.
Does zinc raise testosterone in men who already get enough?
No. In the three studies that gave zinc to men with adequate dietary intake and measured testosterone under controlled conditions, none found a change in total or free testosterone. Koehler and colleagues at the German Sport University Cologne, working in the anti-doping laboratory that tests athletes' urine, published the most careful of them in the European Journal of Clinical Nutrition in 2009. Fourteen healthy, regularly exercising men aged 22 to 33, whose baseline zinc intake had been measured at 11.9 to 23.2 mg a day, took ZMA, a supplement supplying 30 mg of zinc with magnesium and vitamin B6, for 56 days. Serum zinc and urinary zinc rose significantly, confirming the supplement was absorbed. Serum total testosterone and free testosterone did not change, and the urinary pattern of testosterone metabolites, which would shift if androgen production or clearance had altered, was unchanged too. The authors' conclusion was that ZMA has no effect on testosterone in men who eat a zinc-sufficient diet. Wilborn and colleagues at Baylor University had reached the same conclusion five years earlier in the Journal of the International Society of Sports Nutrition: 42 resistance-trained men took ZMA or placebo for eight weeks of supervised training; serum zinc rose 11 to 17 percent in the ZMA group, and there was no difference in total testosterone, free testosterone, IGF-1, cortisol, strength, or body composition. The logic is the same as with vitamin D, where supplementation raises testosterone in deficient men and does nothing in replete men. An enzyme that already has the zinc it needs runs no faster when more arrives; the surplus is excreted in urine, which is exactly what Koehler's urinary zinc measurement showed. The practical consequence is that a man who eats meat, shellfish or dairy regularly, and who therefore takes in the 11 to 15 mg a day that most omnivorous Western diets supply, has no testosterone reason to add a zinc supplement.
The One Positive ZMA Trial, Whose Placebo Group Lost a Fifth of Its IGF-1 in Eight Weeks
Percent change over eight weeks of spring practice in Brilla and Conte, Journal of Exercise Physiology Online 2000, in which 27 NCAA Division II football players took ZMA, a formula of 30 mg zinc monomethionine aspartate, 450 mg magnesium aspartate and 10.5 mg vitamin B6, or placebo. Free testosterone rose 32.4 percent on ZMA, from 132.1 to 176.3 pg/mL, and fell 10.5 percent on placebo. IGF-1 rose 3.6 percent on ZMA and fell 21.5 percent on placebo. Isokinetic leg strength rose 11.6 percent on ZMA and 4.6 percent on placebo. The study was funded by SNAC Systems, the maker of ZMA, whose founder Victor Conte was the second author. The placebo declines are unusually large for a routine training block and account for much of the between-group difference, baseline zinc status was not reported, and the result has not been reproduced: Wilborn 2004 in 42 resistance-trained men over eight weeks found no change in total or free testosterone, IGF-1, cortisol, strength or body composition on ZMA versus placebo, and Koehler 2009 in 14 men with measured zinc intake of 11.9 to 23.2 mg a day found no change in serum total or free testosterone or in urinary testosterone metabolites after 56 days, despite a significant rise in serum and urinary zinc.
- ZMA
- Placebo
Does ZMA work? What did the football-player trial find, and why did it not replicate?
ZMA's reputation rests on one 8-week study of 27 football players published in an online journal in 2000, funded by the company that sold the product, and its central finding has failed to replicate in two independent studies since. Brilla and Conte reported the trial in the Journal of Exercise Physiology Online. Twenty-seven NCAA Division II football players took either ZMA, a formula of 30 mg of zinc as zinc monomethionine aspartate, 450 mg of magnesium aspartate and 10.5 mg of vitamin B6, or placebo during eight weeks of spring practice. Free testosterone rose 32.4 percent in the ZMA group, from 132.1 to 176.3 pg/mL, and fell 10.5 percent on placebo. IGF-1 rose 3.6 percent on ZMA and fell 21.5 percent on placebo. Leg strength measured on an isokinetic dynamometer rose 11.6 percent on ZMA and 4.6 percent on placebo. Victor Conte, the second author, was the founder of SNAC Systems, which manufactured ZMA, and would three years later become the central figure in the BALCO doping investigation. The trial has three problems apart from its funding. The placebo group's 21.5 percent fall in IGF-1 and 10.5 percent fall in free testosterone during a routine spring practice period are unusually large declines that inflate the between-group difference. The players' baseline zinc status was not reported, and college athletes in heavy training have among the highest zinc losses of any group, so the trial may have been a repletion study in disguise. And the result has not been reproduced. Wilborn 2004, with 42 men and a longer supervised training protocol, found no hormone or strength effect. Koehler 2009, with direct measurement of dietary zinc intake, found no effect in men who were demonstrably replete. A related pair of Turkish studies by Kilic and colleagues, in 10 elite wrestlers in 2006 and 10 sedentary men in 2007, gave 3 mg per kilogram of zinc sulfate a day for four weeks and found that the drop in testosterone that follows exhaustion exercise was prevented, but neither study had a placebo group and both measured only the acute response to a single bout. ZMA is not harmful at its labelled dose; 30 mg of zinc sits under the 40 mg upper limit. It is simply a product whose one supporting trial has the profile of a result that will not hold, and whose two replications did not.
The One Positive ZMA Trial, Whose Placebo Group Lost a Fifth of Its IGF-1 in Eight Weeks
Percent change over eight weeks of spring practice in Brilla and Conte, Journal of Exercise Physiology Online 2000, in which 27 NCAA Division II football players took ZMA, a formula of 30 mg zinc monomethionine aspartate, 450 mg magnesium aspartate and 10.5 mg vitamin B6, or placebo. Free testosterone rose 32.4 percent on ZMA, from 132.1 to 176.3 pg/mL, and fell 10.5 percent on placebo. IGF-1 rose 3.6 percent on ZMA and fell 21.5 percent on placebo. Isokinetic leg strength rose 11.6 percent on ZMA and 4.6 percent on placebo. The study was funded by SNAC Systems, the maker of ZMA, whose founder Victor Conte was the second author. The placebo declines are unusually large for a routine training block and account for much of the between-group difference, baseline zinc status was not reported, and the result has not been reproduced: Wilborn 2004 in 42 resistance-trained men over eight weeks found no change in total or free testosterone, IGF-1, cortisol, strength or body composition on ZMA versus placebo, and Koehler 2009 in 14 men with measured zinc intake of 11.9 to 23.2 mg a day found no change in serum total or free testosterone or in urinary testosterone metabolites after 56 days, despite a significant rise in serum and urinary zinc.
- ZMA
- Placebo
What does the 2023 systematic review conclude?
The 2023 systematic review by Te, Liu, Ma and Wang in the Journal of Trace Elements in Medicine and Biology concluded that zinc deficiency reduces testosterone, that zinc supplementation improves it, and that the size of the effect depends on where a man starts. The authors screened the literature and included 38 papers, 8 in humans and 30 in animals. Across the human studies, serum zinc correlated positively with total testosterone, and supplementation raised testosterone in populations that were deficient, including dialysis patients, infertile men and older men with marginal status. The review identified four variables that governed the size of the response: baseline zinc status, baseline testosterone, the chemical form of zinc, and the elemental dose and duration. It described moderate supplementation as playing a role in improving androgen levels and did not endorse high doses. The review's limits are the limits of the field. Eight human papers is a thin base, most of them are more than 25 years old, only one is double-blind and placebo-controlled, the largest has no control group, and no study has followed men for longer than six months. There is no meta-analysis that pools zinc's effect on testosterone, because the studies are too heterogeneous in population and design to pool honestly. A 2020 narrative review by Santos and Teixeira in The Aging Male reached the same conclusion from a clinical angle, describing medicinal doses of zinc as a reasonable adjunct in hypogonadal men who are deficient, while noting that the evidence did not support zinc as a treatment for hypogonadism in men whose zinc was normal. The consensus is therefore unusually clear for a supplement: zinc works as a corrective and not as an enhancer.
Testosterone Up 86 Percent, Sperm Count Doubled, and the Pituitary Signals Fell by Half
Percent change from baseline to six months in the zinc group of Mahajan and colleagues, Annals of Internal Medicine 1982, the only double-blind placebo-controlled zinc trial with testosterone as an endpoint. Twenty stable men on hemodialysis three times a week were randomized to 50 mg of elemental zinc as zinc acetate or placebo, ten per arm. In the zinc group plasma zinc rose from 75 to 100 micrograms per decilitre, serum testosterone from 2.8 to 5.2 ng/mL, and sperm count from 30 to 63 million per mL, each at p under 0.001; luteinizing hormone fell from 92 to 49 mIU/mL at p under 0.005 and follicle-stimulating hormone from 45 to 25 at p under 0.05. The placebo group showed none of these changes. A testosterone rise accompanied by a fall in the gonadotropins that drive it is the signature of a testis that has become more responsive, which is what repletion of a missing cofactor should look like. The men were uremic and started with plasma zinc near the bottom of the normal range, so the result describes correction of deficiency and not enhancement in replete men.
How much zinc did the trials use, and which form?
The human trials used 30 to 57 mg of elemental zinc a day for six weeks to six months, and the form varied from gluconate to acetate to sulfate without any trial comparing them. Prasad's older men took 30 mg as zinc gluconate for three to six months. The three ZMA studies used 30 mg as zinc monomethionine aspartate for eight weeks. Mahajan's dialysis trial used 50 mg as zinc acetate for six months. Jalali's dialysis study used 250 mg of zinc sulfate, which is about 57 mg of elemental zinc, for six weeks. The FAZST trial, the largest randomized zinc study ever run in men, gave 2,370 men in couples seeking fertility treatment 30 mg of zinc with 5 mg of folic acid or placebo for six months and reported in JAMA in 2020 that semen quality and live birth rates did not improve, and that the zinc group had more gastrointestinal side effects; testosterone was not a reported endpoint, and the men were not selected for deficiency. Three practical points follow from the dosing data. First, the recommended dietary allowance for adult men is 11 mg a day, and a man who eats beef, oysters, poultry, dairy or legumes regularly usually meets it; the 2020 NHANES analysis by Reider and colleagues estimated that about 15 percent of Americans fall below the estimated average requirement, with the share higher in adults over 70. Second, the doses that raised testosterone in deficient men, 30 to 50 mg, are three to five times the RDA and sit at or above the 40 mg tolerable upper limit, which is why they are appropriate as a short course under supervision and not as a permanent addition. Third, zinc form matters less than the label suggests: sulfate, gluconate, acetate, citrate and picolinate are all absorbed adequately on an empty stomach, phytate in whole grains and legumes is the main thing that blocks absorption, and vegetarians are advised to consume about 50 percent more zinc for that reason. A man who wants to know whether zinc is relevant to him can have serum zinc measured; a value below about 70 micrograms per decilitre suggests deficiency, though serum zinc is an imperfect marker that falls with inflammation and after meals.
More Than 100 mg a Day, or Ten Years of Use, and the Rate of Advanced Prostate Cancer More Than Doubled
Multivariable relative risk of advanced prostate cancer by supplemental zinc use in Leitzmann and colleagues, Journal of the National Cancer Institute 2003, with 95 percent confidence intervals shown as error bars. The Health Professionals Follow-up Study followed 46,974 US men from 1986 to 2000, recording 2,901 prostate cancers, 434 of them advanced. Supplemental zinc up to 100 mg a day was not associated with prostate cancer. Men taking more than 100 mg a day had a relative risk of 2.29 for advanced disease, confidence interval 1.06 to 4.95, and men who had used zinc supplements for ten or more years had a relative risk of 2.37, interval 1.42 to 3.95, after adjustment for age, family history, body mass, smoking, physical activity, diet and other supplement use. The association is observational and cannot establish cause, but the prostate is the most zinc-rich organ in the body and the finding has not been contradicted by a later cohort of comparable size. Zinc doses that raised testosterone in deficient men were 30 to 57 mg a day for six weeks to six months, well below the 100 mg threshold and, in most cases, at or under the 40 mg tolerable upper limit.
Is zinc safe? What about copper and prostate cancer?
Zinc is safe at dietary doses and up to the 40 mg tolerable upper limit, but doses of 50 mg or more taken for months deplete copper, and men taking more than 100 mg a day had more than twice the rate of advanced prostate cancer in the largest cohort that has looked. The copper problem is well characterized. Zinc induces metallothionein in the gut lining, which binds copper and blocks its absorption; at 50 mg a day or more for several months this produces copper deficiency, whose signs are anemia, low neutrophil counts, and a myeloneuropathy with numbness and unsteady gait that can be permanent if not caught. The clearest human demonstration came from denture-cream users: a 2008 series in Neurology by Nations and colleagues described patients using large amounts of zinc-containing denture adhesive who developed severe copper deficiency with neurological damage. The prostate signal is the finding men over 40 should weigh most carefully. Leitzmann and colleagues analysed 46,974 men in the Health Professionals Follow-up Study, followed from 1986 to 2000, and published in the Journal of the National Cancer Institute in 2003. Over 14 years there were 2,901 prostate cancers, 434 of them advanced. Supplemental zinc intake up to 100 mg a day was not associated with prostate cancer. Men taking more than 100 mg a day had a relative risk of 2.29 for advanced prostate cancer, with a 95 percent confidence interval of 1.06 to 4.95, and men who had used zinc supplements for ten or more years had a relative risk of 2.37, with an interval of 1.42 to 3.95. The association is observational and cannot prove cause; men taking very high zinc doses may differ in other ways, and the authors adjusted for the obvious ones. But the prostate is the most zinc-rich organ in the body, prostate cells handle the metal differently once they turn malignant, and a doubling of advanced disease in long-term high-dose users is not a finding to wave away on the strength of an in vitro aromatase study. Other effects are minor by comparison: nausea and stomach upset are common above 40 mg, especially on an empty stomach, and zinc lozenges taken for colds are the usual route to accidental chronic excess. This article is educational and is not medical advice.
More Than 100 mg a Day, or Ten Years of Use, and the Rate of Advanced Prostate Cancer More Than Doubled
Multivariable relative risk of advanced prostate cancer by supplemental zinc use in Leitzmann and colleagues, Journal of the National Cancer Institute 2003, with 95 percent confidence intervals shown as error bars. The Health Professionals Follow-up Study followed 46,974 US men from 1986 to 2000, recording 2,901 prostate cancers, 434 of them advanced. Supplemental zinc up to 100 mg a day was not associated with prostate cancer. Men taking more than 100 mg a day had a relative risk of 2.29 for advanced disease, confidence interval 1.06 to 4.95, and men who had used zinc supplements for ten or more years had a relative risk of 2.37, interval 1.42 to 3.95, after adjustment for age, family history, body mass, smoking, physical activity, diet and other supplement use. The association is observational and cannot establish cause, but the prostate is the most zinc-rich organ in the body and the finding has not been contradicted by a later cohort of comparable size. Zinc doses that raised testosterone in deficient men were 30 to 57 mg a day for six weeks to six months, well below the 100 mg threshold and, in most cases, at or under the 40 mg tolerable upper limit.
How should a man over 40 use this evidence?
A man over 40 should treat zinc as a nutrient to check and correct, not as a supplement to take on speculation, because the evidence shows a large effect in deficient men and no effect in replete ones. The first practical step is to find out which group he belongs to. A diet with regular red meat, poultry, shellfish or dairy generally supplies the 11 mg a day the RDA calls for, and a man on that diet with normal serum zinc has no testosterone reason to supplement and a documented prostate reason not to overdo it. Men at genuine risk of deficiency are a recognizable group: those on largely plant-based diets, where phytate blocks absorption; heavy drinkers, because alcohol increases urinary zinc loss; men with inflammatory bowel disease, bariatric surgery or chronic kidney disease, where absorption is poor or losses are high; men on long-term diuretics or proton pump inhibitors; and older men in general, because intake falls and absorption declines with age. For those men a serum zinc test is cheap, and if it comes back low a course of 25 to 40 mg of elemental zinc for two to three months, with copper at 1 to 2 mg alongside it and a repeat testosterone panel at the end, is the approach the trial data support. The second step is to hold the effect size in proportion. The men in Prasad's repletion group went from 239 to 461 ng/dL, which is a change that would matter to anyone, but they were deficient at baseline and in their mid-60s; a replete 45-year-old should expect nothing, and the ZMA studies show that is exactly what he gets. The third step is to respect the ceiling. Nothing in the testosterone literature supports doses above 50 mg, the copper data argue against them past a few months, and the prostate cohort argues against them for years. A man who has been taking a 50 mg zinc capsule daily for a long time because a bottle said testosterone on the front should probably stop, get a zinc and copper level, and have the conversation with a physician about whether there was ever a deficiency to correct. The gaps that remain are real: no trial has tested zinc in middle-aged men with low-normal testosterone and normal zinc, no trial has run longer than six months, and nobody has measured whether the testosterone rise in deficient men changes how they feel, which is the question that actually matters.
Testosterone Up 86 Percent, Sperm Count Doubled, and the Pituitary Signals Fell by Half
Percent change from baseline to six months in the zinc group of Mahajan and colleagues, Annals of Internal Medicine 1982, the only double-blind placebo-controlled zinc trial with testosterone as an endpoint. Twenty stable men on hemodialysis three times a week were randomized to 50 mg of elemental zinc as zinc acetate or placebo, ten per arm. In the zinc group plasma zinc rose from 75 to 100 micrograms per decilitre, serum testosterone from 2.8 to 5.2 ng/mL, and sperm count from 30 to 63 million per mL, each at p under 0.001; luteinizing hormone fell from 92 to 49 mIU/mL at p under 0.005 and follicle-stimulating hormone from 45 to 25 at p under 0.05. The placebo group showed none of these changes. A testosterone rise accompanied by a fall in the gonadotropins that drive it is the signature of a testis that has become more responsive, which is what repletion of a missing cofactor should look like. The men were uremic and started with plasma zinc near the bottom of the normal range, so the result describes correction of deficiency and not enhancement in replete men.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Is NAD+ a Peptide? No. It Is a Coenzyme Built From Two Nucleotides, and the Peptide Label Comes From the Clinic, Not the Chemistry
Is NAD+ a peptide? No. NAD+ is a coenzyme built from two nucleotides. What NAD+ is used for, what IV NAD+ studies found, and how it differs from SS-31.
Epitalon vs Pinealon: One Lab Built Both. Epitalon Has an FDA Review and Three Small Human Studies. Pinealon's Case Rests Mostly on Cell Dishes and Rats.
Epitalon vs pinealon compared: structure, targets, sleep and melatonin data, brain studies, human evidence, FDA status, and whether stacking them is tested.
Epithalon vs Epitalon: Same Peptide, Two Spellings. The Name That Means Something Different Is Epithalamin, and Most of the Human Data Belong to It.
Epithalon vs epitalon: one AEDG tetrapeptide, two spellings. Why epithalamin is a different substance and what FDA found in its 2026 epitalon review.